Suppr超能文献

肝凝集素对含岩藻糖糖蛋白的结合。对血液清除率、与膜受体及纯凝集素结合的重新研究。

The binding of fucose-containing glycoproteins by hepatic lectins. Re-examination of the clearance from blood and the binding to membrane receptors and pure lectins.

作者信息

Lehrman M A, Pizzo S V, Imber M J, Hill R L

出版信息

J Biol Chem. 1986 Jun 5;261(16):7412-8.

PMID:3011783
Abstract

The nature of the hepatic receptors that bind glycoproteins through fucose at the non-reducing termini of oligosaccharides in glycoproteins has been examined by three different approaches. First, the clearance from blood of intravenously injected glycoproteins was examined in mice with the aid of neoglycoproteins of bovine serum albumin (BSA). The clearance of fucosyl-BSA was rapid and was not strongly inhibited by glycoproteins that inhibit clearance mediated by the galactose or the mannose/N-acetylglucosamine receptors of liver. The clearance of Fuc alpha 1,3(Gal beta 1,4)GlcNAc-BSA (where Fuc is fucose) was inhibited weakly by either Fuc-BSA or Gal beta 1,4GlcNAc-BSA but strongly by a mixture of the two neoglycoproteins, suggesting that its clearance was mediated by hepatic galactose receptors as well as by a fucose-binding receptor. Second, the binding of neoglycoproteins to a membrane fraction of mouse liver was examined. Fuc-BSA binding to membranes was Ca2+ dependent but was not inhibited by glycoproteins that would inhibit the galactose or the mannose/N-acetylglucosamine receptors. In addition, the binding of Fuc-BSA and Gal beta 1,4GlcNAc-BSA differed as a function of pH, in accord with binding of Fuc-BSA through fucose-specific hepatic receptors. Finally, the binding of neoglycoproteins to the pure galactose lectin from rat liver was examined. Neither Fuc-BSA nor Fuc alpha 1,2Gal beta 1,4GlcNAc-BSA bound the galactose lectin, although Fuc alpha 1,3(Gal beta-1,4) GlcNAc-BSA bound avidly. Taken together, these studies suggest that a fucose-binding receptor that differs from the galactose and the mannose/N-acetylglucosamine receptors may exist in rat and mouse liver.

摘要

通过三种不同方法研究了糖蛋白中寡糖非还原末端通过岩藻糖结合糖蛋白的肝受体的性质。首先,借助牛血清白蛋白(BSA)的新糖蛋白,在小鼠中检测静脉注射糖蛋白从血液中的清除情况。岩藻糖基-BSA的清除速度很快,并且不受抑制肝脏半乳糖或甘露糖/N-乙酰葡糖胺受体介导的清除的糖蛋白的强烈抑制。Fucα1,3(Galβ1,4)GlcNAc-BSA(其中Fuc是岩藻糖)的清除受到Fuc-BSA或Galβ1,4GlcNAc-BSA的微弱抑制,但受到这两种新糖蛋白混合物的强烈抑制,这表明其清除是由肝脏半乳糖受体以及岩藻糖结合受体介导的。其次,检测了新糖蛋白与小鼠肝脏膜部分的结合。Fuc-BSA与膜的结合依赖于Ca2+,但不受抑制半乳糖或甘露糖/N-乙酰葡糖胺受体的糖蛋白的抑制。此外,Fuc-BSA和Galβ1,4GlcNAc-BSA 的结合随pH的变化而不同,这与Fuc-BSA通过岩藻糖特异性肝受体的结合情况一致。最后,检测了新糖蛋白与大鼠肝脏纯半乳糖凝集素的结合。Fuc-BSA和Fucα1,2Galβ1,4GlcNAc-BSA均不与半乳糖凝集素结合,尽管Fucα1,3(Galβ-1,4)GlcNAc-BSA能 avidly 结合。综上所述,这些研究表明大鼠和小鼠肝脏中可能存在一种不同于半乳糖和甘露糖/N-乙酰葡糖胺受体的岩藻糖结合受体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验